Loading quotes...

Forecast

Buy	1
Hold	1
Sell	0

News Go to news feed

Taro Pharmaceuticals recalls nearly 90,000 bottles of children's ibuprofen

Taro Pharmaceuticals is recalling nearly 90,000 bottles of Children's Ibuprofen Oral Suspension after complaints of a gel-like mass and black particles in the bottles. The liquid, a berry-flavored pain reliever for ages 2 to 11, was manufactured in India by Strides Pharma and distributed nationwide. The FDA classified the action as a Class II recall (D-0390-2026). » More on cbsnews.com
Loop Industries delivers recycled DMT to Taro Plast for automotive and specialty polymers

Loop Industries has signed a supply agreement with Taro Plast for recycled dimethyl terephthalate (DMT) from the planned "Infinite Loop India" facility. The JV plant with Ester Industries is slated to start in early 2028 and will produce DMT and up to 70,000 tonnes of PET resin annually. Taro Plast plans to use the 100% recycled DMT in automotive and specialty polymer applications; independent tests confirm its purity and performance. The agreement expands Loop's market into specialty polymers and diversifies revenue sources, while the company remains unprofitable despite reduced operating cash spend. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2018, Taro Pharm Aktie has already paid €11.20 in dividends. The last payout was in December 2018.

Financials

In the last year, Taro Pharm Aktie had revenue of €582.98M and net profit of €49.91M

(EUR)	2024	YoY
Revenue	582.98M	10.61%
Gross profit	282.58M	14.48%
Net profit	49.91M	113.23%
EBITDA	35.58M	26.54%

Fundamentals

Metric	Value
Market capitalization	€1.44B
Number of shares	37.58M
52-week high/low	€40.70 - €29.06
Dividends	No
Beta	0.56
P/E ratio	30.05
PEG ratio	0.26
P/B ratio	0.90
P/S ratio	2.57

Company profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.